ISABIAL, Instituto de Investigación Sanitaria y Biomédica de Alicante

What ISABIAL, Instituto de Investigación Sanitaria y Biomédica de Alicante does

ISABIAL (Instituto de Investigación Sanitaria y Biomédica de Alicante) is a public, non-profit health research institute (foundation CIF G42641308) based at Hospital General Universitario Dr. Balmis in Alicante, Valencian Community, Spain. It was initially accredited by the Instituto de Salud Carlos III in February 2020 and reaccredited in February 2025. The institute operates as a tripartite collaboration among the Departamento de Salud Alicante-Hospital General (Conselleria de Sanitat), Universidad de Alicante (UA), and Universidad Miguel Hernández (UMH), and is governed under the Valencian Community's regional authority.

ISABIAL conducts multidisciplinary, translational biomedical research organized into five strategic areas — neurosciences, endocrinology/metabolism, translational medicine, digestive pathology, and cancer — supported by 48 research groups and more than 670 affiliated researchers. The institute operates 15 specialized research platforms including the Biobank, Bioinformatics, Clinical Analysis and Genetics, Pharmacogenetics, Phase I Clinical Trials Unit (UECA), Clinical Research Unit (UIC), SimIA Simulation Laboratory, and the BioFab joint 3D biomanufacturing unit (the first in the Valencian Community authorized to manufacture custom medical devices). It integrates the TriNetX global real-world data network (220+ organizations, 30 countries, 275M+ patients) and uses REDCap, iFundanet, Microsoft Outlook 365, and Acumbamail as core operational systems. Outputs to date include over 2,200 scientific publications, 115+ competitive research projects, and 353 active clinical trials.

The institute does not operate a commercial revenue model. Funding flows from three streams: (1) competitive public grants from national (ISCIII, Ministerio de Ciencia, Innovación y Universidades), regional (Generalitat Valenciana), and European (ERDF) sources; (2) institutional partnership agreements with UA, UMH, and the Alicante Health Department; and (3) voluntary donations processed via REDSYS. External participants pay €600 for instructor training courses, while internal Alicante Department of Health staff access training for free. ISABIAL is pursuing technology transfer via its Innovation department (CPI), has filed at least one patent application on epigenetic antifibrotic compounds, and was awarded the 2024 FECYT national award for Responsible Research and Innovation for its OPEN DAYS citizen engagement program.

Name

ISABIAL, Instituto de Investigación Sanitaria y Biomédica de Alicante

Legal name

FUNDACIÓN DE LA COMUNITAT VALENCIANA PARA LA GESTIÓN DEL INSTITUTO DE INVESTIGACIÓN SANITARIA Y BIOMÉDICA DE ALICANTE (ISABIAL)

Website

https://isabial.es

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

51–100 employees

Short description

ISABIAL is a public, non-profit biomedical research institute in Alicante, Spain, accredited by ISCIII and jointly operated with two universities and the Alicante Health Department. It runs 48 research groups across five therapeutic areas, 353 clinical trials, and 15 specialized research platforms including a region-first 3D biomanufacturing unit.

Ownership category

akta.pro rank

Product category

Biomedical Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro industry

PRIMARYHLAGAJAM

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

SECONDARYHLAKAEAL

Liver & GI Clinical Research (Trials Centers)

Healthcare & Life Sciences/Specialist Medical Practice/Gastroenterology & Hepatology

Keywords

• Biomedical research
• Clinical trials
• Translational medicine
• Health research
• Scientific innovation

Headquarters

HQ city

Alicante

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Competitive Research Funding: Public funding from national (Instituto de Salud Carlos III), regional (Generalitat Valenciana), and European sources for competitive research projects
2. Institutional Partnerships: Collaboration agreements with Universidad de Alicante, Universidad Miguel Hernández, and the Alicante Health Department
3. Donations: Voluntary contributions from individuals and organizations to support specific research projects

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

ISABIAL is a multidisciplinary translational biomedical research institute that integrates basic, clinical, epidemiological, and health services research across five strategic areas (neurosciences, endocrinology/metabolism, translational medicine, digestive pathology, and cancer). It operates 48 research groups and provides specialized research platforms (biobank, bioinformatics, 3D biomanufacturing, clinical trials units, simulation laboratory, and pharmacogenetics) along with training programs and technology transfer services to improve clinical care quality.

Differentiator

Problem solved

Functional benefit

Products and services

• BioFab - Joint Unit in Biomedical Design and 3D Printing (Unidad Mixta de Investigación en Diseño y Fabricación Biomédica)
• UECA - Alicante Phase I Clinical Trials Unit (Unidad de Ensayos Clínicos de Alicante Fase I)
• UIC - Clinical Research Unit (Unidad de Investigación Clínica)
• SimIA - Simulation and Innovation Laboratory of Alicante (Laboratorio de Simulación e Innovación de Alicante)

Quantifiable outcome

• Reduced hypoglycemia risk by 50% through ENDOCARE protocol for hospitalized diabetes type 2 patients
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration9 records

AI capability8 records

Feature9 records

Partnerships

Seven partnerships are on record, tiered core.

• FECYT (Spanish Foundation for Science and Technology)coreStrategic or Co-development Partner · 11 November 2024UCC+I Network membership strengthening scientific outreach and citizen engagement in health research.
• Universidad de Alicante (UA)coreStrategic or Co-development PartnerUniversity partner contributing academic research expertise to ISABIAL. UA collaborates on joint research units including the BioFab 3D printing unit and various biomedical research projects.
• Universidad Miguel Hernández (UMH)coreStrategic or Co-development PartnerUniversity partner providing research expertise in areas including hepatology, immunology, and epigenetics. UMH researchers collaborate on various ISABIAL research projects and co-lead studies.
• Departamento de Salud Alicante-Hospital GeneralcoreStrategic or Co-development PartnerHealthcare provider and primary clinical research partner. The Hospital General Universitario Dr. Balmis serves as the main clinical setting for ISABIAL research activities.
• Generalitat ValencianacoreStrategic or Co-development PartnerRegional government providing institutional support and funding through the Consellería de Sanitat. Key funder of research activities and infrastructure.
• Instituto de Salud Carlos III (ISCIII)coreStrategic or Co-development PartnerNational health research institute providing official accreditation as Health Research Institute and funding for competitive research projects through national calls.
• CIBER (Biomedical Research Networks)coreStrategic or Co-development PartnerCollaborative research through various CIBER thematic areas including CIBERehd (Hepatic and Digestive Diseases), contributing researchers and resources to national research networks.

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer): One of Spain's leading ISCIII-accredited biomedical research institutes, affiliated with Hospital Clínic Barcelona. Comparable structure (university + hospital + regional government), broad thematic coverage, and active clinical trial operations make it a benchmark peer.
• IBIMA Plataforma BIONAND: ISCIII-accredited biomedical research institute in Málaga integrating hospital, university, and regional government. Comparable multi-thematic structure with a strong clinical trials operation.
• IDIVAL (Instituto de Investigación Sanitaria Valdecilla): ISCIII-accredited Spanish health research institute affiliated with Hospital Universitario Marqués de Valdecilla in Santander. Similar mid-tier regional scale, structure (university + regional health authority), and translational mandate.
• IRBLleida (Institut de Recerca Biomèdica de Lleida): Catalan biomedical research institute with similar institutional architecture (university + regional health service) and ISCIII recognition. Comparable mid-size scope and clinical research focus.
• IIS La Fe (Instituto de Investigación Sanitaria La Fe): The largest health research institute in the Valencian Community, also ISCIII-accredited and covering multiple research areas with strong clinical trial activity. Most direct geographic and structural comparable to ISABIAL within the same regional health system.
• CIPF (Centro de Investigación Príncipe Felipe): Valencia-based biomedical research centre and an existing ISABIAL partner (joint Electron Microscopy unit). Locally adjacent, multi-area biomedical focus, and a structural operational comparable.
• IDIS (Instituto de Investigación Sanitaria de Santiago de Compostela): ISCIII-accredited health research institute in Galicia affiliated with complex hospital and university partners. Similar translational/biomedical research mandate and regional focus.
• IIS Aragón (Instituto de Investigación Sanitaria Aragón): ISCIII-accredited regional health research institute coordinating hospital, university, and regional government activity in Aragón. Comparable governance and translational research mandate.
• IMIB (Instituto Murciano de Investigación Biosanitaria): ISCIII-accredited regional biomedical research institute in Murcia, covering multiple clinical research areas with a similar governance model involving regional government and universities. Comparable scale and operating model.

Broad incumbents

• CNIO (Centro Nacional de Investigaciones Oncológicas): Spain's national oncology research centre; larger and much better funded than ISABIAL with a focused mandate in cancer (one of ISABIAL's 5 areas). Offers a reference point for scale and depth rather than direct competition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/isabial_iis
• YouTubeyoutube.com/@isabial
• LinkedInlinkedin.com/company/fundaci%C3%B3n-isabial
• Instagraminstagram.com/iis_isabial

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ISABIAL, Instituto de Investigación Sanitaria y Biomédica de Alicante